Search

Institute of Oncology Ljubljana and Institute of microbiology and immunology, Slovenia

Unité Inserm 1312 - Bordeaux Institute of Oncology, University of Bordeaux and Plateforme Oncoprot (TBMCore 3427 - US005, Bordeaux Biologie Santé)

Institute of Oncology Ljubljana, The University Clinic of Pulmonary and Allergic Diseases Golnik, and Tanja Znidaric, Principal Investigator

Helse Bergen Hospital Trust, Stichting Trimbos-Instituut, Hannover Medical School, Universiteti i Tiranes, Public Health Center of MOH of Ukraine, German Cancer Research Center, University of Stirling, University of Limerick, Institut d'Investigació Biomèdica de Bellvitge, German Network for Tobacco Free Healthcare Services, The University of Queensland, Dreamedsoft Solutions, Catalan Institute of Oncology, Barcelona, Istituto per lo Studio, la Prevenzione e la Rete Oncologica, and Hidde van der Ploeg, Professor

Institut National de la Santé Et de la Recherche Médicale, France, University Hospital Tuebingen, University of Florence, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, University Of Perugia, German Cancer Research Center, Karolinska Institutet, Maria Sklodowska-Curie National Research Institute of Oncology, Institut Curie, Medical University of Gdansk, Princess Maxima Center for Pediatric Oncology, and Catalan Institute of Oncology, Barcelona

Gynecologic Cancer Intergroup (GCIG), Canadian Institutes of Health Research (CIHR), Korean Gynecologic Oncology Group, Dutch Gynecologic Oncology Group, Cancer Trials Ireland, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, Belgium Gynecologic Oncology Group, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Institute of Cancer Research, United Kingdom, Shanghai Cancer Centre Deptartment of Gynecologic Oncology Fudan University, Hertzen Moscow Scientific Research Institute of Oncology, Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom Germany, and Institut Claudius Regaud - Institute Universitaire du Cancer de Toulouse - Oncopole

Vall d'Hebron Institute of Oncology and AstraZeneca

Tubingen University Hospital, Maria Sklodowska-Curie National Research Institute of Oncology, Fondazione IRCCS ISTITUTO NAZIONALE TUMORI, Hospital Clinic of Barcelona, Istanbul University, University Of Perugia, German Cancer Research Center, and Daniela Massi, Professor

Universita degli Studi di Genova, Cliniche Humanitas Gavazzeni, Università Politecnica delle Marche, European Institute of Oncology, University of Arizona, and Andrea DeCensi, Director of Medical Oncology Division

European Institute of Oncology

Maria Sklodowska-Curie National Research Institute of Oncology, Łukasiewicz Research Network, Wrocław University of Environmental and Life Sciences, and Anna Raciborska, Prof Ass MD PhD

Maria Sklodowska-Curie National Research Institute of Oncology, Łukasiewicz Research Network, Wrocław University of Environmental and Life Sciences, and Anna Raciborska, Prof Ass

Maria Sklodowska-Curie National Research Institute of Oncology, Łukasiewicz Research Network, Wrocław University of Environmental and Life Sciences, and Anna Raciborska, Prof Ass

IRCCS Ospedale San Raffaele, University Hospital of Cologne, St. Antonius Hospital, Istituto Europeo di Oncologia, University Hospital, Udine, Italy, Azienda Ospedaliera San Giovanni Battista, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Lund University, Medical University of Warsaw, Ziekenhuis Netwerk Antwerpen (ZNA), and Dr. Pawel G. Rajwa, Principal Investigator

Maria Sklodowska-Curie National Research Institute of Oncology

Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, and IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto

Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, and IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto

Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, and IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, European Institute of Oncology, University of Alberta, Imperial College London, University of Debrecen, Lithuanian University of Health Sciences, and Milena Pitashny, MD, Director of Clinical and Research Microbiome Center

Vall d'Hebron Institute of Oncology and The Netherlands Cancer Institute

Merck Sharp & Dohme LLC and European Institute of Oncology

European Institute for Biomedical Imaging Research (EIBIR), Austria, University Hospital, Aachen, Vall d'Hebron Institute of Oncology, Mitera Hospital, Radboud University Medical Center, UMC Utrecht, Ribera Salud Hospitals, Spain, Fraunhofer Institute for Digital Medicine (MEVIS), Germany, University Hospital, Zürich, and Cambridge University Hospitals NHS Foundation Trust

Hôpital Edouard Herriot, Maria Sklodowska-Curie National Research Institute of Oncology, Nuovo Regina Margherita Hospital, Karolinska Institutet, Humanitas Clinical and Research Center, Medical University of Gdansk, Universitätsklinikum Hamburg-Eppendorf, University Hospital, Akershus, Vestre Viken Hospital Trust, University Hospital of North Norway, Helse Stavanger HF, Oslo University Hospital, and Michael Bretthauer, Co-Principal Investigator

ASST Santi Paolo e Carlo and European Institute of Oncology

Vall d'Hebron Institute of Oncology and Hospital Universitario La Fe

Maria Sklodowska-Curie National Research Institute of Oncology and Anna Raciborska, Head od Department of Oncology and Surgical Oncology for Children and Youth; Prof. Ass. PhD MD

Kazakh Research Institute of Oncology & Radiology

Kazakh Research Institute of Oncology & Radiology, Montreal EpiTerapia Inc., and Canada-Kazakhstan EpiTerapia Inc.

Kazakh Research Institute of Oncology & Radiology

Gustave Roussy, Cancer Campus, Grand Paris, Centre Leon Berard, Vall d'Hebron Institute of Oncology, Istituto Europeo di Oncologia, and Charite University, Berlin, Germany

European Commission, Simbec-Orion Group Ltd, Merthyr Tydfil, UK, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, Leiden University Medical Center, LUMC, Leiden, The Netherlands, Centre Hospitalier Universitaire de Nancy, CHU, Vandoeuvre-Lès-Nancy, France, Ghent University Hospital, UZG, Ghent, Belgium, Ospedale Pediatrico Bambino Gesù, OPBG, Rome, Italy, Newcastle University, UNEW, Newcastle, UK, Vall d'Hebron Institute of Oncology (VHIO) and Banc de Sang I Teixits (BST), Barcelona, Spain, and Prof. Tobias Feuchtinger, Prof. Dr. med Tobias Feuchtinger

All India Institute of Medical Sciences, New Delhi, Cancer Foundation of India, Christian Fellowship Community Health Centre, German Cancer Research Center, Gujarat Cancer & Research Institute, Jehangir Clinical Development Centre, MNJ Institute of Oncology and Regional Cancer Center, Rajiv Gandhi Centre for Biotechnology, Nargis Datta Memorial Cancer Hospital, Tata Memorial Centre, and Partha Basu, Early Detection, Prevention and Infection Branch at IARC, WHO

European Institute of Oncology, Changhua Christian Hospital, Samsung Medical Center, and Hyung Seok Park, MD, PhD, Clinical Associate Professor

Vall d'Hebron institute of oncology (VHIO), Catalan institute of oncology (Hospitalet) (ICO)

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice and Wojciech Kaspera, Principal Investigator

European Institute of Oncology, Philipps University Marburg, Ernst von Bergmann Hospital, Chinese University of Hong Kong, Wolfson Medical Center, University of Belgrade, Harvard University, University of Salamanca, and Francesco Zaraca, MD PhD Privat Dozent

Institute of Oncology Research

Associazione Italiana per la Ricerca sul Cancro, European Institute of Oncology, and Andrea DeCensi, Medical Oncology Director

Istituto Oncologico Veneto IRCCS, Ospedale Policlinico San Martino, Federico II University, Azienda Policlinico Umberto I, European Institute of Oncology, Ospedale 'Carlo Poma' - Mantova, and Humanitas Clinical and Research Center

S. Andrea Hospital, Azienda Policlinico Umberto I, Azienda Ospedaliero, Universitaria Pisana, Università degli Studi dell'Aquila, University of Milan, Azienda Ospedaliera di Perugia, Monaldi Hospital, Azienda Ospedaliera di Bolzano, AUSL Romagna Rimini, European Institute of Oncology, Università degli Studi di Ferrara, and Azienda Socio Sanitaria Territoriale di Mantova

Maria Sklodowska-Curie National Research Institute of Oncology

Institute of Oncology Research (IOR), Istituto Cantonale di Patologia, and Ricardo Pereira Mestre, MD

Kolfarma s.r.l. - Italy, European Institute of Oncology, and Claudio De Felice, Principal Investigator

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, European Institute of Oncology, Regina Elena Cancer Institute, and Baxter Healthcare Corporation

Specialized Medical Services (SMS)-Oncology BV, Royal Marsden NHS Foundation Trust, Northern Institute for Cancer Research, Newcastle, Vall d'Hebron Institute of Oncology, Instituto Oncológico IMQ, Clínica IMQ Zorrotzaurre. Bilbao, and Onkologikoa, San Sebastián.

IFOM ETS - The AIRC Institute of Molecular Oncology, European Institute of Oncology, and University of Milan

Vall d'Hebron Institute of Oncology, Shaare Zedek Medical Center, LungenClinic Grosshansdorf, Metropolitan Hospital, Athens, University of Chicago, and Arsela Prelaj, Principal Investigator

Federico II University, Agnelli Hospital, Italy, Ospedale della Misericordia, Candiolo Cancer Institute - IRCCS, Maggiore Bellaria Hospital, Bologna, Università degli Studi di Ferrara, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliera Universitaria Policlinico 'G. Martino', Ospedale Policlinico San Martino, University of Rome Tor Vergata, S. Andrea Hospital, and European Institute of Oncology

Oncology Institute of Southern Switzerland, Institute of Oncology Research, Institute for Research in Biomedicine, and Ricardo Pereira Mestre, MD

Medical University of Graz, Université Catholique de Louvain, Hospital de Câncer de Barretos, University Hospital Rijeka, Evangelische Kliniken Gelsenkirchen, University Medical Center Freiburg, University Hospital Regensburg, Sheba Medical Center, Instituto Nazionale Tumori Fondazione Pascale, Istituto Oncologico Veneto IRCCS, Oslo University Hospital, Jagiellonian University, Oncology Department Hospital of Navarre, University of Leeds, The Netherlands Cancer Institute, Tumor- und Brust-zentrum ZeTuP St. Gallen, National Taiwan University, Taipei Veterans General Hospital, Taiwan, National Center for Global Health and Medicine, Japan, King Hussein Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Kansai Medical University, Tikur Anbessa Hospital, Tata Memorial Hospital, and Mekelle University